[1] SACCO R L，KARGMAN D E，GU Q，et al.

Race-ethnicity and determinants of intracranial

atherosclerotic cerebral infarction. The Northern

Manhattan Stroke Study[J]. Stroke，1995，26（1）：

14-20.

[2] WONG L K. Global burden of intracranial

atherosclerosis[J]. Int J Stroke，2006，1（3）：158-159.

[3] WANG Y，ZHAO X，LIU L，et al. Prevalence and

outcomes of symptomatic intracranial large artery

stenoses and occlusions in China：the Chinese

Intracranial Atherosclerosis（CICAS）Study[J].

Stroke，2014，45（3）：663-669.

[4] QURESHI A I，CAPLAN L R. Intracranial

atherosclerosis[J]. Lancet，2014，383（9921）：984-998.

[5] KERN R，STEINKE W，DAFFERTSHOFER M，et

al. Stroke recurrences in patients with symptomatic

vs asymptomatic middle cerebral artery disease[J].

Neurology，2005，65（6）：859-864.

[6] MAZIGHI M，TANASESCU R，DUCROCQ

X，et al. Prospective study of symptomatic

atherothrombotic intracranial stenoses：the GESICA

study[J]. Neurology，2006，66（8）：1187-1191.

[7] CHIMOWITZ M I，LYNN M J，DERDEYN C P，et

al. Stenting versus aggressive medical therapy for

intracranial arterial stenosis[J]. N Engl J Med，2011，

365（11）：993-1003.

[8] JUNG J M，KANG D W，YU K H，et al. Predictors

of recurrent stroke in patients with symptomatic

intracranial arterial stenosis[J]. Stroke，2012，43

（10）：2785-2787.

[9] TURAN T N，COTSONIS G，LYNN M J，et al.

Intracranial stenosis：Impact of randomized trials

on treatment preferences of US neurologists and

neurointerventionists[J]. Cerebrovasc Dis，2014，37

（3）：203-211.

[10] DERDEYN C P，CHIMOWITZ M I，LYNN M J，et

al. Aggressive medical treatment with or without

stenting in high-risk patients with intracranial

artery stenosis（SAMMPRIS）：the final results of a

randomized trial[J]. Lancet，2014，383（9914）：333-

341.

[11] ZAIDAT O O，FITZSIMMONS B F，WOODWARD

B K，et al. Effect of a balloon-expandable

intracranial stent vs medical therapy on risk of stroke

in patients with symptomatic intracranial stenosis：

the VISSIT randomized clinical trial[J]. JAMA，

2015，313（12）：1240-1248.

[12] CHIMOWITZ M I，LYNN M J，HOWLETT-SMITH

H，et al. Comparison of warfarin and aspirin for

symptomatic intracranial arterial stenosis[J]. N Engl

J Med，2005，352（13）：1305-1316.

[13] CHATURVEDI S，TURAN T N，LYNN M J，et al.

Do Patient Characteristics Explain the Differences

in Outcome Between Medically Treated Patients in

SAMMPRIS and WASID?[J] Stroke，2015，46（9）：

2562-2567.

[14] WONG K S，CHEN C，FU J，et al. Clopidogrel

plus aspirin versus aspirin alone for reducing

embolisation in patients with acute symptomatic

cerebral or carotid artery stenosis（CLAIR study）：a

randomised，open-label，blinded-endpoint trial[J].

Lancet Neurol，2010，9（5）：489-497.

[15] LIU L，WONG K S，LENG X，et al. Dual

antiplatelet therapy in stroke and ICAS：Subgroup

analysis of CHANCE[J]. Neurology，2015，85（13）：

1154-1162.

[16] KERNAN W N，OVBIAGELE B，BLACK H R，et

al. Guidelines for the prevention of stroke in patients

with stroke and transient ischemic attack：a guideline

for healthcare professionals from the American Heart

Association/American Stroke Association[J]. Stroke，

2014，45（7）：2160-2236.

[17] KIM J S，NAH H W，PARK S M，et al. Risk factors

and stroke mechanisms in atherosclerotic stroke：

intracranial compared with extracranial and anterior compared with posterior circulation disease[J].

Stroke，2012，43（12）：3313-3318.

[18] FLYNN J T，FALKNER B E. New Clinical

Practice Guideline for the Management of High

Blood Pressure in Children and Adolescents[J].

Hypertension，2017，70（4）：683-686.

[19] CHATURVEDI S，TURAN T N，LYNN M J，et

al. Risk factor status and vascular events in patients

with symptomatic intracranial stenosis[J]. Neurology，

2007，69（22）：2063-2068.

[20] TURAN T N，COTSONIS G，LYNN M J，et al.

Relationship between blood pressure and stroke

recurrence in patients with intracranial arterial

stenosis[J]. Circulation，2007，115（23）：2969-2975.

[21] PARK J H，OVBIAGELE B，HONG K S，et

al. Association of Systolic Blood Pressure

with Progression of Symptomatic Intracranial

Atherosclerotic Stenosis[J]. J Stroke，2017，19（3）：

304-311.

[22] YU D D，PU Y H，PAN Y S，et al. High Blood

Pressure Increases the Risk of Poor Outcome at

Discharge and 12-month Follow-up in Patients with

Symptomatic Intracranial Large Artery Stenosis

and Occlusions：Subgroup analysis of the CICAS

Study[J]. CNS Neurosci Ther，2015，21（6）：530-

535.

[23] WANG J G，STAESSEN J A，LI Y，et al. Carotid

intima-media thickness and antihypertensive

treatment：a meta-analysis of randomized controlled

trials[J]. Stroke，2006，37（7）：1933-1940.

[24] MORTSELL D，MALMQVIST K，HELD C，et al.

Irbesartan reduces common carotid artery intimamedia

thickness in hypertensive patients when

compared with atenolol：the Swedish Irbesartan

Left Ventricular Hypertrophy Investigation versus

Atenolol（SILVHIA）study[J]. J Intern Med，2007，

261（5）：472-479.

[25] BAE H J，LEE J，PARK J M，et al. Risk factors

of intracranial cerebral atherosclerosis among

asymptomatics[J]. Cerebrovasc Dis，2007，24（4）：

355-360.

[26] HUANG H W，GUO M H，LIN R J，et al.

Prevalence and risk factors of middle cerebral artery

stenosis in asymptomatic residents in Rongqi County，

Guangdong[J]. Cerebrovasc Dis，2007，24（1）：111-

115.

[27] CARVALHO M，OLIVEIRA A，AZEVEDO

E，et al. Intracranial arterial stenosis[J]. J Stroke

Cerebrovasc Dis，2014，23（4）：599-609.

[28] AMARENCO P，LABREUCHE J，LAVALLEE

P，et al. Statins in stroke prevention and carotid

atherosclerosis：systematic review and up-to-date

meta-analysis[J]. Stroke，2004，35（12）：2902-2909.

[29] BAIGENT C，KEECH A，KEARNEY P M，et al.

Efficacy and safety of cholesterol-lowering treatment：

prospective meta-analysis of data from 90，056

participants in 14 randomised trials of statins[J].

Lancet，2005，366（9493）：1267-1278.

[30] AMARENCO P，BOGOUSSLAVSKY J，

CALLAHAN A 3RD，et al. High-dose atorvastatin

after stroke or transient ischemic attack[J]. N Engl J

Med，2006，355（6）：549-559.

[31] AMARENCO P，GOLDSTEIN L B，SZAREK

M，et al. Effects of intense low-density lipoprotein

cholesterol reduction in patients with stroke or

transient ischemic attack：the Stroke Prevention

by Aggressive Reduction in Cholesterol Levels

（SPARCL）trial[J]. Stroke，2007，38（12）：3198-

3204.

[32] TAN T Y，KUO Y L，LIN W C，et al. Effect of lipidlowering

therapy on the progression of intracranial

arterial stenosis[J]. J Neurol，2009，256（2）：187-

193.

[33] WANG J，WU J，ZHANG S，et al. Elevated fasting

glucose as a potential predictor for asymptomatic

cerebral artery stenosis：a cross-sectional study in

Chinese adults[J]. Atherosclerosis，2014，237（2）：

661-665.

[34] SKYLER J S，BERGENSTAL R，BONOW R O，et

al. Intensive glycemic control and the prevention of

cardiovascular events：implications of the ACCORD，

ADVANCE，and VA diabetes trials：a position

statement of the American Diabetes Association

and a scientific statement of the American College

of Cardiology Foundation and the American Heart

Association[J]. Circulation，2009，119（2）：351-357.

[35] CHENG L，JIAO L，GAO P，et al. Risk factors

associated with in-hospital serious adverse events

after stenting of severe symptomatic intracranial

stenosis[J/OL]. Clin Neurol Neurosurg，2016，147：

59-63. https：//doi.org/10.1016/j.clineuro.2016.05.019.

[36] ROTHWELL P M，ELIASZIW M，GUTNIKOV S

A，et al. Endarterectomy for symptomatic carotid

stenosis in relation to clinical subgroups and timing

of surgery[J]. Lancet，2004，363（9413）：915-924.

[37] KASNER S E，CHIMOWITZ M I，LYNN M J，et

al. Predictors of ischemic stroke in the territory

of a symptomatic intracranial arterial stenosis[J].

Circulation，2006，113（4）：555-563.

[38] TOPAKIAN R，STRASAK A M，SONNBERGER

M，et al. Timing of stenting of symptomatic carotid

stenosis is predictive of 30-day outcome[J]. Eur J Neurol，2007，14（6）：672-678.

[39] MIAO Z，JIANG L，WU H，et al. Randomized

controlled trial of symptomatic middle cerebral

artery stenosis：endovascular versus medical therapy

in a Chinese population[J]. Stroke，2012，43（12）：

3284-3290.

[40] JIA B，FENG L，LIEBESKIND D S，et al.

Mechanical thrombectomy and rescue therapy for

intracranial large artery occlusion with underlying

atherosclerosis[J/OL]. J Neurointerv Surg，2017. http：

//dx.doi.org/10.1136/neurintsurg-2017-013489.

[41] AI HASAN M，MURUGAN R. Stenting versus

aggressive medical therapy for intracranial arterial

stenosis：more harm than good[J]. Crit Care，2012，

16（3）：310.

[42] CHENG X Q，TIAN J M，ZUO C J，et al.

Hemodynamic alterations in unilateral chronic

middle cerebral artery stenosis patients and the

effect of percutaneous transluminal angioplasty and

stenting：a perfusion-computed tomography study[J].

Acta Radiol，2015，56（6）：754-760.

[43] DUAN G，FENG Z，ZHANG L，et al. Solitaire

stents for the treatment of complex symptomatic

intracranial stenosis after antithrombotic failure：

safety and efficacy evaluation[J]. J Neurointerv Surg，

2016，8（7）：680-684.

[44] YU S C，LEUNG T W，HUNG E H，et

al. Angioplasty and stenting for intracranial

atherosclerotic stenosis with nitinol stent：

factors affecting technical success and patient

safety[J/OL]. Neurosurgery，2012，70（1 Suppl

Operative）：104-113. https：//doi.org/10.1227/

NEU.0b013e3182320bb0.

[45] SUN X，TONG X，LO W T，et al. Risk Factors of

Subacute Thrombosis After Intracranial Stenting

for Symptomatic Intracranial Arterial Stenosis[J].

Stroke，2017，48（3）：784-786.

[46] LIEBESKIND D S，COTSONIS G A，SAVER J

L，et al. Collaterals dramatically alter stroke risk in

intracranial atherosclerosis[J]. Ann Neurol，2011，69

（6）：963-974.

[47] 中国卒中学会脑血流与代谢分会. 缺血性卒中脑侧支

循环评估与干预中国指南（2017）[J]. 中华内科杂志，

2017，56（6）：460-471.

[48] WANG Y，CHEN J M，LIU X，et al. Evaluation

of the combined application of ultrasound imaging

techniques for middle cerebral artery stent

surveillance and follow-up study[J/OL]. PLoS

One，2013，8（11）：e79410. https：//doi.org/10.1371/

journal.pone.0079410.

[49] HAN Y F，LIU W H，CHEN X L，et al. Severity

assessment of intracranial large artery stenosis

by pressure gradient measurements：A feasibility

study[J]. Catheter Cardiovasc Interv，2016，88（2）：

255-261.

[50] MIAO Z，LIEBESKIND D，LO W，et al. Fractional

Flow Assessment for the Evaluation of Intracranial

Atherosclerosis：A Feasibility Study[J]. Interv

Neurol，2016，5（1-2）：65-75.

[51] SUNDT T M JR，SMITH H C，CAMPBELL J K，

et al. Transluminal angioplasty for basilar artery

stenosis[J]. Mayo Clin Proc，1980，55（11）：673-

680.

[52] OKADA H，TERADA T，TANAKA Y，et al.

Reappraisal of primary balloon angioplasty without

stenting for patients with symptomatic middle

cerebral artery stenosis[J]. Neurol Med Chir（Tokyo），

2015，55（2）：133-140.

[53] MARKS M P，WOJAK J C，AL-ALI F，et al.

Angioplasty for symptomatic intracranial stenosis：

clinical outcome[J]. Stroke，2006，37（4）：1016-

1020.

[54] TERADA T，HIGASHIDA R T，HALBACH V V，

et al. Transluminal angioplasty for arteriosclerotic

disease of the distal vertebral and basilar arteries[J].

J Neurol Neurosurg Psychiatry，1996，60（4）：377-

381.

[55] GRUBER P，GARCIA-ESPERON C，BERBERAT J，

et al. Neuro Elutax SV drug-eluting balloon versus

Wingspan stent system in symptomatic intracranial

high-grade stenosis：a single-center experience[J/

OL]. J Neurointerv Surg，2018. http：//dx.doi.

org/10.1136/neurintsurg-2017-013489.

[56] VON SCHOENFELDT P，KRÜTZELMANN，

BUβMEYER M，et al. Elective treatment of

intracranial stenosis with the balloon-expandable

Pharos Vitesse stent：30-day stroke rate and

complications[J]. J Neurointerv Surg，2015，7（3）：

188-193.

[57] MIAO Z，ZHANG Y，SHUAI J，et al. Thirty-Day

Outcome of a Multicenter Registry Study of Stenting

for Symptomatic Intracranial Artery Stenosis in

China[J]. Stroke，2015，46（10）：2822-2829.

[58] FIORELLA D，LEVY E I，TURK A S，et al. US

multicenter experience with the wingspan stent

system for the treatment of intracranial atheromatous

disease：periprocedural results[J]. Stroke，2007，38

（3）：881-887.

[59] LI T X，GAO B L，CAI D Y，et al. Wingspan

Stenting for Severe Symptomatic Intracranial

Atherosclerotic Stenosis in 433 Patients Treated

at a Single Medical Center[J/OL]. PloS One，2015，10（9）：e0139377. https：//doi.org/10.1371/journal.

pone.0139377.

[60] JIANG W J，YU W，DU B，et al. Outcome of

patients with ≥70% symptomatic intracranial

stenosis after Wingspan stenting[J]. Stroke，2011，42

（7）：1971-1975.

[61] VAJDA Z，SCHMID E，GÜTHE T，et al. The

modified Bose method for the endovascular

treatment of intracranial atherosclerotic arterial

stenoses using the Enterprise stent[J]. Neurosurgery，

2012，70（1）：91-101.

[62] VAJDA Z，GUTHE T，PEREZ M A，et al.

Prevention of intracranial in-stent restenoses：

predilatation with a drug eluting balloon，followed

by the deployment of a self-expanding stent[J].

Cardiovasc Intervent Radiol，2013，36（2）：346-352.

[63] DUAN G，FENG Z，ZHANG L，et al. Solitaire

stents for the treatment of complex symptomatic

intracranial stenosis after antithrombotic failure：

safety and efficacy evaluation[J]. J Neurointerv Surg，

2016，8（7）：680-684.

[64] HÄHNEL S，RINGLEB P，HARTMANN

M. Treatment of intracranial stenoses using the

Neuroform stent system：initial experience in five

cases[J]. Neuroradiology，2006，48（7）：479-485.

[65] KING S B 3RD，SMITH S C JR，HIRSHFELD J W

JR，et al. 2007 Focused Update of the ACC/AHA/

SCAI 2005 Guideline Update for Percutaneous

Coronary Intervention：a report of the American

College of Cardiology/American Heart Association

Task Force on Practice Guidelines：2007 Writing

Group to Review New Evidence and Update the ACC/

AHA/SCAI 2005 Guideline Update for Percutaneous

Coronary Intervention，Writing on Behalf of the

2005 Writing Committee[J]. Circulation，2008，117

（2）：261-295.

[66] SMITH S C JR，FELDMAN T E，HIRSHFELD J

W JR，et al. ACC/AHA/SCAI 2005 guideline update

for percutaneous coronary intervention：a report of

the American College of Cardiology/American Heart

Association Task Force on Practice Guidelines（ACC/

AHA SCAI Writing Committee to Update 2001

Guidelines for Percutaneous Coronary Intervention）

[J]. Circulation，2006，113（1）：156-175.

[67] LI X，MA N，SUN S，et al. Association of genetic

variant and platelet function in patients undergoing

neuroendovascular stenting[J]. Postgrad Med J，2017，

93（1103）：555-559.

[68] ZHAO Z，LI X，SUN S，et al. Impact of

genetic polymorphisms related to clopidogrel

or acetylsalicylic acid pharmacology on clinical

outcome in Chinese patients with symptomatic

extracranial or intracranial stenosis[J]. Eur J Clin

Pharmacol，2016，72（10）：1195-1204.

[69] ZAIDAT O O. Periprocedural management of

patients with endovascular treatment of intracranial

atherosclerotic disease[J]. J Neuroimaging，2009，19

（Suppl 1）：S35-S38.

[70] MIAO Z，SONG L，LIEBESKIND D S，et al.

Outcomes of tailored angioplasty and/or stenting

for symptomatic intracranial atherosclerosis：a

prospective cohort study after SAMMPRIS[J]. J

Neurointerv Surg，2015，7（5）：331-335.

[71] LAIWALLA A N，OOI Y C，VAN DE WIELE B，

et al. Rigorous anaesthesia management protocol

for patients with intracranial arterial stenosis：a

prospective controlled-cohort study[J/OL]. BMJ

Open，2016，6（1）：e009727. http：//dx.doi.

org/10.1136/bmjopen-2015-009727.

[72] NAHAB F，LYNN M J，KASNER S E，et al. Risk

factors associated with major cerebrovascular

complications after intracranial stenting[J].

Neurology，2009，72（23）：2014-2019.

[73] FIORELLA D，DERDEYN C P，LYNN M J，et

al. Detailed analysis of periprocedural strokes

in patients undergoing intracranial stenting in

Stenting and Aggressive Medical Management for

Preventing Recurrent Stroke in Intracranial Stenosis

(SAMMPRIS）[J]. Stroke，2012，43(10）：2682-2688.

[74] JIANG W J，YU W，MA N，et al. High resolution

MRI guided endovascular intervention of basilar

artery disease[J]. J Neurointerv Surg，2011，3（4）：

375-378.